Objective. Serological markers are thought to be useful in predicting which patients with early inflammatory arthritis (EIA) will progress to RA. The objective of this study is to determine the per cent RF and anti-CCP seroconversion in EIA patients at 1-5 years of follow-up: 80% of established RA is RF or CCP positive.
Introduction
Early diagnosis of RA is important in order to initiate DMARD treatment, which is known to slow progression of disease and is more effective in patients with shorter disease duration [1] [2] [3] . Patients presenting with early inflammatory arthritis (EIA) may progress to RA. Identifying which of these patients progress to RA is thought to be beneficial as early DMARD therapy may improve outcomes. It has been proposed that RF and anti-CCP, in addition to clinical features, may predict progression to RA in patients with EIA [4] .
RF is an antibody directed at the Fc region of immunoglobulin G. Its sensitivity in established RA is 70-80% and its specificity is 78% [5] . The sensitivity and specificity is lower in early RA (ERA) [6] ; however, it has been shown to be predictive of RA development in EIA and it is an important prognostic marker as its presence is associated with more severe disease, radiographic erosions and extra-articular manifestations [4, [7] [8] [9] [10] . Anti-CCP, on the other hand, has a very low false-positive rate (<3%), even in patients with early disease, but has low sensitivity (40-55%) [11] . For patients with EIA, Van Gaalen et al. [12] demonstrated a positive likelihood ratio for RA of 16.7. Similar to RF, anti-CCP is a marker of worse outcomes in ERA.
Since studies to date show that RF and anti-CCP are important prognostic markers and that anti-CCP has high specificity for RA, it may be important to determine whether patients with EIA initially negative for RF and anti-CCP become positive in the future. The objective of this systematic review is to determine RF and anti-CCP seroconversion (negative to positive) in EIA patients over time. This article is part of the 3E (Evidence, Expertise and Exchange) initiative described elsewhere [13] .
Materials and methods

Literature search
We performed a search of the following bibliographic data- Our search study combined terms for 'undifferentiated inflammatory peripheral arthritis', 'rheumatoid factor' and 'anti-cyclic citrullinated peptides' (for full search strategy see appendix 1, available as supplementary data at Rheumatology Online).
Study selection
Citations were first screened by title and abstract to retrieve relevant articles. The retrieved articles were then reviewed in full, applying the following inclusion criteria: patients aged >15 years with EIA that we defined as having at least one swollen joint and <2 years of symptoms. EIA patients consisted of those with undifferentiated inflammatory polyarthritis (UIPA), defined as not meeting ACR criteria for any rheumatic condition, ERA, defined as meeting ACR criteria for RA, or mixed populations (patients with UIPA, ERA or meeting ACR criteria for rheumatic diseases other than RA). The topic for the 2008 3E initiative was the diagnosis and prognosis of UIPA; unfortunately, there were only two studies that addressed RF and anti-CCP seroconversion in UIPA. Therefore, we included studies on other populations of EIA. Case reports, case series, reviews and articles in languages other than English were excluded. Papers with unclear follow-up times were also excluded. A hand search of the references in relevant papers was also conducted to identify any additional articles addressing our objective.
Data extraction and quality appraisal
We extracted from the included papers the publication details, patient characteristics, length of follow-up, per cent baseline and follow-up RF positivity and anti-CCP positivity and, if available, per cent negative to positive seroconversion of RF and anti-CCP. Data were extracted only from assays measuring immunoglobulin M RF and anti-CCP2. All included papers underwent methodological quality assessment using the Newcastle Ottawa Scale (NOS) for cohort studies (http://www.ohri.ca/programs/ clinical_epidemiology/nosgen.pdf) [14] . This scale assigns asterisks for higher quality features of studies in three domains: selection (maximum of four asterisks), comparability (maximum of two asterisks) and outcome (maximum of three asterisks). All studies, regardless of NOS score, were included in the review.
Results
Search results
A summary of the search results and reference selection is shown in appendix 2 (available as supplementary data at Rheumatology Online). We identified 412 full-length articles and 27 abstracts from ACR and EULAR meetings. Most of these were excluded by screening of the title and abstract, leaving 50 articles for full review. Of these, eight were included in the systematic review. The other studies were excluded because of failure to provide follow-up data on RF or anti-CCP positivity or because values for seroconversion were not given. Four congress abstracts also met our inclusion criteria, for a total of 12 studies included in this review [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Interestingly, only two studies (both Congress Abstracts: [20, 22] ) directly addressed our objective; the other studies contained information on RF and anti-CCP seroconversion in the text or the figures. Table 1 shows the characteristics of the included studies. Ten studies included information on RF and five discussed anti-CCP. Only two studies [15, 16] had populations with UIPA. All others contained mixed populations (six studies) or ERA (four studies). Machold et al. [19] and Nell et al. [26] reported two different populations (mixed and ERA, respectively) from the same cohort (the Early Arthritis Action cohort) [27] . Sample size ranged from 15 to 395 and follow-up from 6 months to a median of 48 months.
Study characteristics
Baseline patient characteristics of the individual studies were also quite variable: mean age 41-59 years, 51-75% females and disease duration from 2 to 12 months. Swollen joint count and treatment before trial enrolment was infrequently disclosed. Most of the studies treated patients post-enrolment with standard of care, but details were generally not given. In the UIPA studies, 7-19% of patients were diagnosed with RA at follow-up and 27-29% remained as UIPA. Three studies with mixed populations reported on the baseline proportion of patients with UIPA and of those with ACR criteria for RA and 46-56%, respectively). Of the UIPA patients in these studies, 30-50% went on to a diagnosis of RA at follow-up. The percentage of patients from the mixed populations with UIPA at follow-up was 15-32 and of those with RA was 61-78.
Methodological quality of studies Studies were assessed using the NOS and total scores ranged from 3 to 7 (Table 2 ) [14] . None of the studies was of high methodological quality (total score 8-9). Three of the studies (including the only two UIPA studies) were of poor quality (scores of 3 and 4). The other studies were of moderate quality, averaging a score of 6. We were unable 18 (29) 92 (59) 38 (35) 65 (33) 2 (5) 11 ( www.rheumatology.oxfordjournals.org to fully assess the quality of the four studies for which only Congress Abstracts were available and therefore scores were not assigned.
RF and anti-CCP positivity
As evident from the characteristics of the included references shown in Table 1 , heterogeneity was too great to allow for pooling of results. Table 1 also shows the per cent RF and anti-CCP positivity at baseline and follow-up, the change in positivity over time and the negative to positive seroconversion. Baseline values of RF and anti-CCP positivity are quite variable across studies: 7.7-73% for RF (RF positivity was zero in Narvaez et al. [21] as RF-positive patients were excluded at baseline) and 3.8-41% for anti-CCP. The number of seropositive patients is lower in the UIPA studies and in studies with shorter disease durations.
Follow-up RF positivity is lowest in studies with short follow-up (7.7% at 6 months and 29% at 9 months) and there was no negative to positive seroconversion at 6-9 months follow-up (Table 1 and Fig. 1 ). For 1 year follow-up studies, change from baseline in per cent RF positivity ranged from 0 to 5 and seroconversion was 1.9-5%. Change in RF positivity and RF per cent seroconversion in studies with > 1 year follow-up was À9 to +7 and 2.6%, respectively.
Three studies reported on the change in anti-CCP positivity over time: 0% at 9 months, 3% at 30 months and 8% at 32 months (Table 1 and Fig. 1) . Seroconversion was 1.3% in a 12-month trial, 6.8% in a 5-year trial and 8.9% in a 30-month trial; however, an update on the same cohort (n = 206) presented at the Canadian Rheumatology Association reported 5.3% seroconversion at 30 months [28] . Changes in RF or anti-CCP positivity were not different among the different populations (UIPA, ERA or mixed).
Discussion
RF and anti-CCP are important diagnostic and prognostic tools in RA. This study addresses the question of seropositivity over time in EIA patients. Unfortunately, only two abstracts from Congress meetings specifically addressed this question; all other studies had different primary and secondary outcomes, which resulted in a lack of details regarding RF and anti-CCP positivity. For example, most studies did not disclose the type of assays used to detect RF, and therefore there is a potential for different sensitivities and specificities. For anti-CCP, this was reduced by only including studies that used the commercially available anti-CCP2 assay. This only excluded two small studies: one of these (n = 41) reported a seroconversion of 2.4% at 11 months, which is consistent with the studies included in this article [23] . The other study (n = 15) only Only abstracts available, full methodological assessment not possible.
FIG. 1 Seroconversion of RF (a) and anti-CCP (b).
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Ates et al. [16] Machold et al. [19] Narvaez et al. [21] Vittecoq et al. [24] Carrier et al. [20] Hulsemann et al. [15] Cordonnier et al. [23] Nell et al. [26] Stockman et al. [18] Green et al. 
Mjavaatten et al. [22] Carrier et al. [20] Nell et al. [26] Flendrie et al. [24] Ates et al. [16] had two anti-CCP-positive patients at baseline and an additional two at follow-up, but numbers were too small to draw conclusions [24] . Titres of RF and anti-CCP were also not generally reported, which may have implications given that higher titres may be more specific for RA and may have further prognostic value [29] .
This systematic review is part of the 2008 3E initiative and, as such, our primary aim was to determine RF and anti-CCP positivity in patients with UIPA; unfortunately, there were only two studies (both of poor methodological quality) in this population group. Because of this, we included mixed populations (with various percentages of UIPA) and ERA. As expected, the UIPA populations had lower baseline RF and anti-CCP positivity, which correlated with their lower per cent RA diagnosis at follow-up (7 and 19%) compared with mixed populations (65-78%). Conclusions regarding RF and anti-CCP positivity over time in UIPA are difficult to draw based on these studies with low sample size and high numbers lost to follow-up; however, it appears that seroconversion in UIPA is very low (reported as zero over a period of up to 2 years). This is consistent with the results from mixed population studies (which were of better quality and consisting of larger sample sizes). These studies, despite the high number of RA diagnoses at follow-up, reported minimal anti-CCP seroconversion (6.8% at 5 years) and a minimal change in RF positivity (5% at of 4 years). In a number of studies, the percentage of RF-positive patients actually declined over time. This was true even in ERA populations. We also do not know what percentage of patients seroconvert from positive to negative RF or anti-CCP over time.
The low RF baseline values and seroconversion rates in the ERA and mixed populations (of which a majority are subsequently diagnosed with RA) do not appear to account for the RF positivity seen in established RA (70-80% at 10-15 years). There are a number of possible explanations for this observation. Seronegative patients may be more likely to remit and become lost to follow-up, which raises the question, might we be over-treating EIA? Conversely, early treatment may be impacting on RF and anti-CCP expression and this may be improving outcomes. Unfortunately, the studies addressing the change in RF and anti-CCP positivity over time did not provide details on the treatment regimens used and therefore it is not possible to draw any conclusions regarding the effect of treatment on seroconversion.
Another explanation is that there has been a decline in the prevalence of seropositive RA or an increase in seronegative RA, which may be a very different entity, possibly requiring a different therapeutic approach. Regardless of the reason, the low seroconversion of RF and anti-CCP suggests that repeat testing at follow-up may not have any added value. It is unknown whether seronegative patients who become positive have worse outcomes or whether seroconversion would have any additional diagnostic utility.
There is very little data on the change in RF and anti-CCP positivity over time in patients with UIPA. Available studies are of poor methodological quality; however, good studies with mixed populations of EIA or ERA suggest that seroconversion rates are low at up to 5 years of follow-up. The reason for the disconnection between established RA cohorts and ERA or UIPA with respect to seropositive rates is unknown. Further studies are needed to elucidate seropositivity over time in patients with UIPA and the diagnostic and prognostic implications of seroconversion. Currently, there are insufficient data to recommend repeat RF and anti-CCP testing at follow-up.
Rheumatology key messages
. Seroconversion rates for EIA were 1.9-5.0% for RF and 1.3-8.9% for anti-CCP. . There is minimal change in RF or anti-CCP positivity with up to 5 years of follow-up in EIA. . Low seroconversion rates of RF in EIA suggest a lower prevalence than that in established RA.
